Encorafenib plus cetuximab before surgery for BRAF-mutated colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign consent.
- Your cancer must be colon or upper rectum (operable) and confirmed as BRAF V600E-mutated from a biopsy.
- Your imaging (CT scan) must show a higher-risk stage: rT3 with at least 5 mm spread outside the bowel wall, or rT4 (spread into a nearby organ).
- Your tumor tissue (or DNA from the tumor) must be enough for central lab testing of BRAF and RAS.
- Your heart rhythm, blood counts, kidney function, and liver blood tests must be within allowed ranges.
- You must not have cancer that has spread to distant sites (M1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.